Rates of kidney stones are increasing in the United States and around the world. Type 2 diabetes is associated with an increased risk of developing kidney stones, but certain types of treatment for the condition may also have the benefit of reducing the risk of developing kidney stones. In a study led by investigators at Mass General Brigham, researchers found an association between the use of sodium-glucose transporter 2 (SGLT2) inhibitors and a reduced risk of developing kidney stones. Their results are reported Jama Internal Medicine.
Researchers from Brigham and Women’s Hospital and Massachusetts General Hospital, a founding member of the Mass General Brigham Health Care System, worked together to conduct the analysis. The study included data from three nationwide databases of patients with type 2 diabetes seen in routine clinical practice. The team analyzed data on 716,406 adults with type 2 diabetes who started taking an SGLT2 inhibitor or GLP1 receptor agonist or two other classes of diabetes drugs known as dipeptidyl peptidase 4 (DPP4) inhibitors. Patients who started taking SGLT2 inhibitors had a 30 percent lower risk of developing kidney stones than those taking GLP1 agonists and about a 25 percent lower risk than those taking DPP4 inhibitors. Results were consistent across gender, race/ethnicity, history of chronic kidney disease, and obesity.
Our findings may help inform clinical decision-making for patients with diabetes who are at risk of developing kidney stones.”
Julie Pike, MD, Sc.D., MPH, Corresponding author Divisions of Pharmacoepidemiology and Pharmacoeconomics and Renal (Kidney) Medicine, Brigham and Women’s Hospital.
Pike, JM, etc. (2024). Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis in patients with type 2 diabetes. Jama Internal Medicine. doi.org/10.1001/jamainternmed.2023.7660.